🟢 Immunic is trading 6.46% up in after-hours trading after announcing September 9 multiple-sclerosis R&D Day

Immunic is trading 6.46% up now at $15.16 after announcing a September 9 virtual R&D Day focused on relapsing multiple sclerosis.

• The event comes ahead of expected year-end Phase 3 ENSURE trial data for vidofludimus calcium, providing a near-term investor catalyst.
• No earnings release or other major company-specific announcement was identified on September 2; the move appears tied primarily to the R&D event and upcoming clinical data.